Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYC translocation + BCL2 translocation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BCL2/BCL2L1 ratio elevation (3)

BCL2 rearrangement + MYC amplification (2)

HR positive + MYC amplification (2)

MYC amplification + ALK F1174L (2)

MYC expression + MYC rearrangement (2)

MYC overexpression + IDH1 mutation (2)

MYC overexpression + IDH2 mutation (2)

MYC rearrangement + LDH elevation (2)

BCL2/MCL1 ratio elevation (2)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

EGFR T790M + MYC amplification (1)

HER-2 positive + MYC amplification (1)

HR positive + MYC mutation (1)

IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

MYC mutation + ER positive (1)

miR-17-HG deletion + MYC positive (1)

BCL2 elevation + IGH elevation (1)

BCL2 fusion + EZH2 mutation (1)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

Chr t(11;14) + BCL2 overexpression (1)

PTEN deletion + BCL2 translocation (1)

BCL2/BAX ratio elevation (0)

BCL2/BCL2L1 ratio elevation (3)

BCL2 rearrangement + MYC amplification (2)

HR positive + MYC amplification (2)

MYC amplification + ALK F1174L (2)

MYC expression + MYC rearrangement (2)

MYC overexpression + IDH1 mutation (2)

MYC overexpression + IDH2 mutation (2)

MYC rearrangement + LDH elevation (2)

BCL2/MCL1 ratio elevation (2)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK positive + MYC amplification + CCND1 deletion (1)

EGFR T790M + MYC amplification (1)

HER-2 positive + MYC amplification (1)

HR positive + MYC mutation (1)

IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)

IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

MYC amplification + BCL2 amplification + TNFRSF8 expression (1)

MYC mutation + ER positive (1)

miR-17-HG deletion + MYC positive (1)

BCL2 elevation + IGH elevation (1)

BCL2 fusion + EZH2 mutation (1)

Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)

Chr t(11;14) + BCL2 overexpression (1)

PTEN deletion + BCL2 translocation (1)

BCL2/BAX ratio elevation (0)

›

MYC translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	MYC translocation + BCL2 translocation	Diffuse Large B Cell Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
MYC translocation + BCL2 translocation	Lymphoma	MYC translocation + BCL2 translocation	Lymphoma	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3